SWOG-9510: Evaluation of topotecan in hormone refractory prostate cancer: A Southwest Oncology Group Study

被引:8
作者
Klein, CE
Tangen, CM
Braun, TJ
Hussain, MHA
Peereboom, DM
Nichols, CR
Rivkin, SE
Dakhil, SR
Crawford, ED
机构
[1] Univ Colorado, Denver, CO 80202 USA
[2] SW Oncol Grp, Ctr Stat, Seattle, WA USA
[3] Wayne State Univ, Med Ctr, Detroit, MI 48202 USA
[4] Cleveland Clin Fdn, Cleveland, OH 44195 USA
[5] Oregon Hlth Sci Univ, Portland, OR 97201 USA
[6] Puget Sound Oncol Consortium, Seattle, WA USA
[7] Wichita Community Clin Oncol Program, Wichita, KS USA
关键词
hormone refractory prostate cancer; topotecan; clinical trial;
D O I
10.1002/pros.10118
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND. Prostate cancer is the most common malignancy in American men, and as many as 70%, of those initially treated for localized disease will ultimately progress and be considered candidates to receive therapy for metastatic cancer [1,2]. Although most will respond initially to hormone manipulation, essentially all will fail and require additional therapy. No standard chemotherapy approach has been shown to prolong survival significantly, and new agents are desperately needed. Topotecan is a now topoisomerase-1 inhibitor whose early investigation suggested possible activity in hormone-refractory prostate cancer. METHODS. In this phase II trial, patients having failed one or two prior androgen ablative therapies were treated with 21-day continuous intravenous infusions of topotecan at a dose of 0.5 mg/m(2) per day every 28 days. RESULTS. Twenty-six eligible patients were entered on the study. There were no confirmed tumor responses. Median survival was 9 months. The most common toxicities were hematologic, with 8 of 24 assessable patients experiencing grade 4 toxicity. CONCLUSION. Topotecan infusions at this dose are ineffective in the management of hormone-refractory prostate cancer.
引用
收藏
页码:264 / 268
页数:5
相关论文
共 20 条
[1]  
CHODAK GW, 1994, NEW ENGL J MED, V330, P246
[2]   THE EFFECT OF LOCAL-CONTROL ON METASTATIC DISSEMINATION IN CARCINOMA OF THE PROSTATE - LONG-TERM RESULTS IN PATIENTS TREATED WITH I-125 IMPLANTATION [J].
FUKS, Z ;
LEIBEL, SA ;
WALLNER, KE ;
BEGG, CB ;
FAIR, WR ;
ANDERSON, LL ;
HILARIS, BS ;
WHITMORE, WF .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1991, 21 (03) :537-547
[3]   DNA TOPOISOMERASE-I TARGETED CHEMOTHERAPY OF HUMAN-COLON CANCER IN XENOGRAFTS [J].
GIOVANELLA, BC ;
STEHLIN, JS ;
WALL, ME ;
WANI, MC ;
NICHOLAS, AW ;
LIU, LF ;
SILBER, R ;
POTMESIL, M .
SCIENCE, 1989, 246 (4933) :1046-1048
[4]   PHASE-I TRIAL OF LOW-DOSE CONTINUOUS TOPOTECAN INFUSION IN PATIENTS WITH CANCER - AN ACTIVE AND WELL-TOLERATED REGIMEN [J].
HOCHSTER, H ;
LIEBES, L ;
SPEYER, J ;
SORICH, J ;
TAUBES, B ;
ORATZ, R ;
WERNZ, J ;
CHACHOUA, A ;
RAPHAEL, B ;
VINCI, RZ ;
BLUM, RH .
JOURNAL OF CLINICAL ONCOLOGY, 1994, 12 (03) :553-559
[5]   EVALUATION OF 9-DIMETHYLAMINOMETHYL-10-HYDROXYCAMPTOTHECIN AGAINST XENOGRAFTS DERIVED FROM ADULT AND CHILDHOOD SOLID TUMORS [J].
HOUGHTON, PJ ;
CHESHIRE, PJ ;
MYERS, L ;
STEWART, CF ;
SYNOLD, TW ;
HOUGHTON, JA .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1992, 31 (03) :229-239
[6]   Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer [J].
Hudes, GR ;
Nathan, F ;
Khater, C ;
Haas, N ;
Cornfield, M ;
Giantonio, B ;
Greenberg, R ;
Gomella, L ;
Litwin, S ;
Ross, E ;
Roethke, S ;
McAleer, C .
JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (09) :3156-3163
[7]   Phase II study of topotecan in metastatic hormone-refractory prostate cancer [J].
Hudes, GR ;
Kosierowski, R ;
Greenberg, R ;
Ramsey, HE ;
Fox, SC ;
Ozols, RF ;
McAleer, CA ;
Giantonio, BJ .
INVESTIGATIONAL NEW DRUGS, 1995, 13 (03) :235-240
[8]   High dose bicalutamide for androgen independent prostate cancer: Effect of prior hormonal therapy [J].
Joyce, R ;
Fenton, MA ;
Rode, P ;
Constantine, M ;
Gaynes, L ;
Kolvenbag, G ;
DeWolf, W ;
Balk, S ;
Taplin, ME ;
Bubley, GJ .
JOURNAL OF UROLOGY, 1998, 159 (01) :149-153
[9]   PROSTATE-SPECIFIC ANTIGEN AS A MEASURE OF DISEASE OUTCOME IN METASTATIC HORMONE-REFRACTORY PROSTATE-CANCER [J].
KELLY, WK ;
SCHER, HI ;
MAZUMDAR, M ;
VLAMIS, V ;
SCHWARTZ, M ;
FOSSA, SD .
JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (04) :607-615
[10]  
LI LH, 1972, CANCER RES, V32, P2643